MMV and DNDi make 400 compounds available to stimulate research into new drugs for pandemic diseases
Medicines for Malaria Venture (MMV) and the Drugs for Neglected Diseases initiative (DNDi) have launched the Pandemic Response Box to provide researchers with free access to 400 diverse compounds to accelerate the discovery of new treatments for life-threatening pandemic diseases. The Pandemic Response Box is a collection of structurally diverse antibacterial, antiviral and antifungal compounds – selected by disease experts – for screening against infective and neglected diseases.
Using local clinical and microbiological data to develop an institution specific carbapenem-sparing strategy in sepsis: a nested case-control study
Merel M. C. Lambregts et al.,
Current guidelines on antibiotic stewardship recommend to adapt empiric therapy to local microbiological data. However, specific recommendations on when and how to change the empiric treatment guidelines in response to increasing resistance rates are lacking. A risk-based approach in empiric sepsis therapy has the potential to better target the use of reserve antimicrobial agents aimed at multi-resistant Gram-negative pathogens.
Webinar Series 2019 on next-generation sequencing for drug-resistant TB
The Webinar Series 2019 on next-generation sequencing for drug-resistant TB will take place on 5, 12, 19, and 26 February 2019. FIND, the World Health Organization, the New Diagnostics Working Group and MSF Access Campaign are co-organizing a four-part webinar series on the use and implementation of next-generation sequencing (NGS) for drug-resistant TB (DR-TB).
Prior dengue in kids may protect against Zika symptoms
Prior dengue infection may protect children from Zika illness symptoms, an international research team reported yesterday, based on data from a longstanding dengue cohort study in Nicaragua.
Drugs ready for distribution
MORE drugs are ready for distribution to hospitals and clinics across the country following their recent arrival and release from the Solomon Islands Ports Authority.
Experts on watch for resistance to new flu drug
Japanese researchers yesterday described two H3N2 flu viruses with mutations that may increase resistance to the new flu antiviral baloxavir marboxil (Xofluza), approved by the US Food and Drug Administration (FDA) in October, a development they say bears watching.
Drones swoop in to deliver life-saving vaccines to remote Vanuatu villages
The drone which soared into South River took about 20 minutes to cover the distance which our boat covered in two hours.
It can travel at more than 100 kilometres an hour, and costs about $4 an hour (in battery power) to run.
New one-dose drug prevents malaria relapse, studies show
Results from trials of tafenoquine, a novel anti-relapse medicine for patients infected with Plasmodium vivax malaria, have shown the drug to be effective and safe, according to a pair of studies published in The New England Journal of Medicine.
Pandemics may cause US$570 billion annual loss to global economy
Outbreak Readiness and Business Impact: Protecting Lives and Livelihoods across the Global Economy describes the business risk posed by a new era of epidemic risk, which can no longer be thought of exclusively in terms of rare but devastating events like global influenza pandemics. The white paper offers recommendations to help companies more appropriately understand risks, reduce exposure and act on opportunities for public-private cooperation to optimally prepare for and mitigate these risks.
MMV 16th call for proposals is now open
Are you a researcher working on compounds or assays with antimalarial potential?
If yes, MMV welcomes proposals for: Drug Discovery Projects, Compounds for Target Identification, Endemic region African projects.